Aurobindo Pharma arm gets 'Voluntary Action Indicated' classification for Telengana facility from USFDA

The Economic Times reported that Apitoria Pharma, a subsidiary of Aurobindo Pharma, received a Voluntary Action Indicated classification from the USFDA for its Telangana facility. The outlet said the classification followed an inspection of the site from September 7 to September 15, 2026. The USFDA is the United States Food and Drug Administration, which inspects plants that make medicines for the US market. A Voluntary Action Indicated classification means the regulator found issues at the site that the company can correct on its own, without the stricter steps that follow more serious findings. The report does not give the number of observations or say which products the facility makes. Aurobindo Pharma is a listed Indian drugmaker, so inspections of its plants matter to how its US business is watched.

AI summary of what Economic Times reported. AI can make mistakes. Read the full story on Economic Times